Medicenna Therapeutics Corp - MDNA STOCK NEWS

Welcome to our dedicated page for Medicenna Therapeutics news (Ticker: MDNA), a resource for investors and traders seeking the latest updates and insights on Medicenna Therapeutics stock.

Medicenna Therapeutics (MDNA) is a clinical-stage immunotherapy company at the forefront of developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs). With a mission to lead in the development and commercialization of targeted ECs and superkines, Medicenna aims to revolutionize treatment for a broad range of cancers and immune-mediated diseases. The company leverages its expertise and collaborates with world-class researchers to create unique superkines.

Medicenna's innovative approach allows these superkines to function either as standalone short or long-acting therapeutics or to be fused with pro-apoptotic proteins. This fusion precisely delivers potent cell-killing agents to cancer cells, the immunosuppressive tumor micro-environment, and cancer stem cells, sparing healthy cells from harm. Additionally, these superkines can be fused with antibodies to create novel 'immunocytokines' or combined with other treatment modalities.

Currently, Medicenna is engaged in various promising projects. A notable recent achievement includes the characterization of its tumor-targeting and activatable T-MASK platform, designed to enhance tumor accumulation and tolerability of potent immune modulators. This innovation was presented at a significant conference on November 3, 2023.

As Medicenna continues to advance its pipeline of targeted treatments, it remains committed to transforming the therapeutic landscape for cancer and immune-related conditions. The company's financial health is supported by strategic partnerships and a focus on groundbreaking research and development.

11/09/2023 08:56 AM

News

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting

Rhea-AI Summary

Medicenna Therapeutics Corp. (MDNA) to present long-term follow-up data from Phase 2b clinical trial of bizaxofusp at SNO 2023 Annual Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/06/2023 07:00 AM

News

Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary

Medicenna Therapeutics Corp. presented new clinical data from the Phase 1 monotherapy dose escalation/evaluation portion of the ABILITY-1 study at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data showed encouraging single-agent activity of MDNA11, with deep partial responses and durable stable disease in advanced solid tumor patients. MDNA11 demonstrated a favorable safety profile with no dose-limiting toxicities reported. The recommended dose for expansion in the monotherapy portion of the study is 90 ug/kg. Results from the Phase 2 study are expected in the first half of 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

22.52%

Tags

11/03/2023 12:00 PM

News

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary

Medicenna Therapeutics Corp. announced preclinical data demonstrating proof of concept for its T-MASK platform technology with its development candidate, MDNA113. The platform enhances tumor specific accumulation and anti-tumor activity while improving the safety profile of immune modulators. MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment. The IL-13Rα2 target is linked to aggressive cancers that affect over 2 million patients annually.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

48.02%

Tags

10/27/2023 07:55 AM

News

Medicenna Announces Nasdaq Delisting and Cutback of Management Team

Rhea-AI Summary

Medicenna Therapeutics Corp. has received a delisting determination from Nasdaq due to its failure to comply with the minimum bid price requirement. The company will not appeal the decision and its common shares will continue to trade on the TSX. The decision was made to save costs and resources associated with a Nasdaq listing. The company anticipates significant financial savings as a result of this decision. The company will also seek to have its common shares traded on the OTC Markets.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-21.51%

Tags

10/25/2023 07:00 AM

News

Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

Rhea-AI Summary

Medicenna announces dosing of first patient in Phase 2 study for MDNA11

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.11%

Tags

10/24/2023 07:15 AM

News

Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)

Rhea-AI Summary

Medicenna Therapeutics Corp. will present an update from its Phase 1/2 ABILITY Study at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. They will also present pre-clinical data for MDNA113, a novel tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 superkine.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.84%

Tags

10/10/2023 07:07 AM

News

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

Rhea-AI Summary

Medicenna Therapeutics Corp. appoints Humphrey Gardner, M.D. as Chief Medical Officer to lead the development of clinical programs.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.45%

Tags

10/03/2023 07:00 AM

News

Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Rhea-AI Summary

Medicenna Therapeutics Corp. presents preclinical data on MDNA223, a bifunctional Superkine for immunotherapy, at AACR Special Conference. MDNA223 shows superior efficacy and extended survival in multiple tumor models, including 'cold' tumors. It demonstrates synergy with pro-inflammatory agonist (STING) and enhances tumor inhibition and abscopal effect. The data highlight the potential of Medicenna's BiSKIT platform for effective therapy in challenging-to-treat tumors.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.21%

Tags

09/28/2023 05:00 PM

News

Medicenna Announces Results of Annual and Special Meeting of Shareholders

Rhea-AI Summary

Medicenna announces successful election of directors with over 97% of votes cast, positive for stock

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.73%

Tags

09/28/2023 07:00 AM

News

Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Rhea-AI Summary

Medicenna to present preclinical results of MDNA223 BiSKIT candidate at AACR Special Conference in Cancer Research. Management to participate in upcoming healthcare and partnering summits.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-5.42%

Tags

FAQ

What does Medicenna Therapeutics specialize in?

Medicenna Therapeutics specializes in developing novel and highly selective versions of IL-2, IL-4, and IL-13 superkines and first-in-class Empowered Cytokines (ECs) for treating cancer and immune-mediated diseases.

What are superkines?

Superkines are engineered cytokines with enhanced properties. They can be used as short or long-acting therapeutics or fused with other proteins to deliver targeted treatments to cancer cells and the tumor micro-environment.

How does Medicenna's T-MASK platform work?

The T-MASK platform is a tumor-targeting and activatable system designed to improve the accumulation and tolerability of potent immune modulators in tumors, sparing healthy tissues.

What are empowered cytokines (ECs)?

Empowered Cytokines (ECs) are enhanced versions of natural cytokines that have been genetically engineered to improve their therapeutic effects and target cancer cells more effectively.

What recent achievements has Medicenna made?

A recent achievement includes the presentation of their T-MASK platform, which enhances tumor accumulation and tolerability of immune modulators, at a major conference on November 3, 2023.

What is the company's mission?

Medicenna's mission is to lead in the development and commercialization of targeted ECs and superkines to treat a broad range of cancers and immune-mediated diseases.

How does Medicenna ensure the safety of its treatments?

Medicenna's treatments are designed to precisely target cancer cells and the tumor micro-environment without harming healthy cells, ensuring a safer therapeutic approach.

What are immunocytokines?

Immunocytokines are cytokines fused with antibodies, combining the properties of both to improve targeting and efficacy in cancer treatment.

How does Medicenna collaborate with other researchers?

Medicenna collaborates with world-class researchers to harness cutting-edge science and expertise, driving innovation in their therapeutic developments.

What is the financial outlook for Medicenna?

Medicenna's financial health is bolstered by strategic partnerships, ongoing research and development, and a pipeline of promising therapeutic candidates.